PBI22 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A SPANISH PERSPECTIVE
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.126
https://www.valueinhealthjournal.com/article/S1098-3015(19)32504-5/fulltext
Title :
PBI22 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A SPANISH PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32504-5&doi=10.1016/j.jval.2019.09.126
First page :
Section Title :
Open access? :
No
Section Order :
10082